BGACF.US BioNeutra Global Corporation
- Market cap
- USD 260K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is BGACF.US undervalued?
Graham numberThe Graham number of BioNeutra Global Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioNeutra Global Corporation fundamental analysis
No fundamental analysis for BioNeutra Global Corporation yet.
BioNeutra Global Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioNeutra Global Corporation
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Cana…
Full company profileBioNeutra Global Corporation financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioNeutra Global Corporation annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.7M | 16.0M | 26.0M | 32.1M | 37.7M | 37.7M | 24.1M | 15.4M | 13.4M | 11.4M | 10.9M |
| Gross Profit | 7.07M | 7.05M | 9.22M | 7.24M | 10.4M | 638K | 3.94M | 2.89M | 2.35M | 4.14M | 2.15M |
| Operating Income | 3.55M | 626K | 2.70M | -22.6K | 3.38M | -9.83M | -3.03M | -2.36M | -2.42M | -1.44M | -2.39M |
| EBITDA | 3.70M | 1.92M | 3.81M | 569K | 6.04M | -10.1M | -1.50M | -1.12M | -1.36M | -352K | -1.21M |
| Net Income | 5.11M | 179K | 1.08M | -1.16M | 3.10M | -12.4M | -3.71M | -2.83M | -2.92M | -2.11M | -2.67M |
| EPS | 0.21 | 0.00 | 0.02 | -0.03 | 0.07 | -0.27 | -0.08 | -0.06 | -0.06 | -0.05 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 13.8M | 26.8M | 36.6M | 31.0M | 40.0M | 34.0M | 23.7M | 21.1M | 19.8M | 15.8M | 13.6M |
| Total Liabilities | 3.19M | 11.6M | 20.8M | 17.0M | 21.9M | 29.3M | 23.0M | 22.1M | 23.5M | 22.0M | 21.8M |
| Shareholders' Equity | 10.6M | 15.2M | 15.8M | 14.0M | 18.1M | 4.75M | 701K | -1.03M | -3.76M | -6.19M | -8.23M |
| Cash & Short-term Investments | 2.08M | 1.63M | 592K | 1.39M | 1.50M | 523K | 934K | 839K | 723K | 1.89M | 797K |
| Total Debt | 288K | 9.11M | 9.98M | 10.1M | 8.94M | 7.58M | 7.07M | 6.89M | 7.01M | 7.64M | 7.54M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.41M | 482K | 1.02M | 2.25M | 2.91M | 708K | 1.43M | 271K | 838K | 683K | -1.21M |
| Capital Expenditure | 58.5K | 9.93M | 2.58M | 2.01M | 823K | 237K | 76.4K | 277K | 204K | 19.3K | 90.2K |
| Free Cash Flow | 1.35M | -9.45M | -1.56M | 233K | 2.08M | 470K | 1.36M | -5.70K | 635K | 664K | -1.30M |
| Ratios | |||||||||||
| ROE | 48.0% | 1.2% | 6.8% | -8.3% | 17.2% | -261.8% | -528.9% | - | - | - | - |
| ROA | 37.0% | 0.7% | 3.0% | -3.7% | 7.8% | -36.6% | -15.7% | -13.4% | -14.8% | -13.4% | -19.7% |
| Net Profit Margin | 32.6% | 1.1% | 4.2% | -3.6% | 8.2% | -33.0% | -15.4% | -18.4% | -21.8% | -18.5% | -24.5% |
| Debt to Equity | 0.03x | 0.60x | 0.63x | 0.72x | 0.49x | 1.59x | 10.09x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioNeutra Global Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | 121K | 0.00 | 67.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioNeutra Global Corporation
- Insiders 36.86%
- Institutions 0.00%
- Public & others 63.14%
- Shares outstanding 46.4M
- Free float 45.9M
BioNeutra Global Corporation company profile
- Company name
- BioNeutra Global Corporation
- Ticker
- BGACF.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Food Products
- Fiscal year end
- December
- Address
- 1030 West Georgia St., Vancouver, BC, Canada, V6E 2Y3
- Phone
- 604-210-5669
- Website
- bioneutra.ca
About BioNeutra Global Corporation
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.
BioNeutra Global Corporation management
3- Dr. Jianhua Zhu Ph.D.Founder, CEO, President & Director
- David Sun C.M.A., CPA, M.A.Chief Financial Officer
- Sheri O'BrienVice President of Sales & Marketing